DOCSLIB.ORG

)&F1y3x PHARMACEUTICAL APPENDIX to THE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE 99-45-6 ACEFURTIAMINE 10072-48-7 AFALANINE 2901-75-9 ACEFYLLINE PIPERAZINE 18428-63-2 AFELIMOMAB 156227-98-4 ACEFYLLINE CLOFIBROL 70788-27-1 AFLOQUALONE 56287-74-2 ACEGLATONE 642-83-1 AFOVIRSEN 151356-08-0 ACEGLUTAMIDE 2490-97-3 AFUROLOL 65776-67-2 ACEMANNAN 110042-95-0 AGANODINE 86696-87-9 ACEMETACIN 53164-05-9 AGLEPRISTONE 124478-60-0 ACENEURAMIC ACID 131-48-6 AKLOMIDE 3011-89-0 ACENOCOUMAROL 152-72-7 ALACEPRIL 74258-86-9 ACEPERONE 807-31-8 ALAFOSFALIN 60668-24-8 ACEPROMAZINE 61-00-7 ALANINE 56-41-7 ACEPROMETAZINE 13461-01-3 ALANOSINE 5854-93-3 ACEQUINOLINE 42465-20-3 ALAPROCLATE 60719-82-6 ACESULFAME 33665-90-6 ALAZANINE TRICLOFENATE 5779-59-9 ACETAMINOSALOL 118-57-0 ALBENDAZOLE 54965-21-8 ACETARSOL 97-44-9 ALBENDAZOLE OXIDE 54029-12-8 ACETAZOLAMIDE 59-66-5 ALBIFYLLINE 107767-55-5 ACETERGAMINE 3031-48-9 ALBUTOIN 830-89-7 ACETIAMINE 299-89-8 ALCLOFENAC 22131-79-9 ACETIROMATE 2260-08-4 ALCLOMETASONE 67452-97-5 ACETOHEXAMIDE 968-81-0 ALCLOXA 1317-25-5 ACETOHYDROXAMIC ACID 546-88-3 ALCURONIUM CHLORIDE 15180-03-7 ACETOPHENAZINE 2751-68-0 ALDESULFONE SODIUM 144-75-2 ACETORPHINE 25333-77-1 ALDIOXA 5579-81-7 ACETRYPTINE 3551-18-6 ALDOSTERONE 52-39-1 ACETYLCHOLINE CHLORIDE 60-31-1 ALENDRONIC ACID 66376-36-1 ACETYLCYSTEINE 616-91-1 ALENTEMOL 112891-97-1 ACETYLDIGITOXIN 1111-39-3 ALEPRIDE 66564-15-6 ACETYLLEUCINE 99-15-0 ALESTRAMUSTINE 139402-18-9 ACETYLMETHADOL 509-74-0 ALEXIDINE 22573-93-9 ACEVALTRATE 25161-41-5 ALEXITOL SODIUM 66813-51-2 ACEXAMIC ACID 57-08-9 ALFACALCIDOL 41294-56-8 ACICLOVIR 59277-89-3 ALFADEX 10016-20-3 ACIFRAN 72420-38-3 ALFADOLONE 14107-37-0 ACIPIMOX 51037-30-0 ALFAPROSTOL 74176-31-1 ACITAZANOLAST 114607-46-4 ALFAXALONE 23930-19-0 ACITEMATE 101197-99-3 ALFENTANIL 71195-58-9 ACITRETIN 55079-83-9 ALFETAMINE 4255-23-6 ACIVICIN 42228-92-2 ALFUZOSIN 81403-80-7 ACLANTATE 39633-62-0 ALGELDRATE 1330-44-5 ACLARUBICIN 57576-44-0 ALGESTONE 595-77-7 ACLATONIUM NAPADISILATE 55077-30-0 ALGLUCERASE 143003-46-7 ACODAZOLE 79152-85-5 ALIBENDOL 26750-81-2 ACONIAZIDE 13410-86-1 ALICONAZOLE 63824-12-4 ACOXATRINE 748-44-7 ALIFEDRINE 78756-61-3 ACRIDOREX 47487-22-9 ALIFLURANE 56689-41-9 ACRIFLAVINIUM CHLORIDE 8063-24-9 ALIMADOL 52742-40-2 ACRIHELLIN 67696-82-6 ALIMEMAZINE 84-96-8 ACRISORCIN 7527-91-5 ALINIDINE 33178-86-8 ACRIVASTINE 87848-99-5 ALIPAMIDE 3184-59-6 ACROCINONIDE 28971-58-6 ALIZAPRIDE 59338-93-1 ACRONINE 7008-42-6 ALLETORPHINE 23758-80-7 ACTAGARDIN ALLOBARBITAL 52-43-7 ACTAPLANIN 37305-75-2 ALLOCLAMIDE 5486-77-1 ACTARIT 18699-02-0 ALLOCUPREIDE SODIUM 5965-40-2 ACTINOQUINOL 15301-40-3 ALLOMETHADIONE 526-35-2 ACTISOMIDE 96914-39-5 ALLOPURINOL 315-30-0 )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 Table 1 (con.) Product CAS Number Product CAS Number ALLYLESTRENOL 432-60-0 AMFONELIC ACID 15180-02-6 ALLYLPRODINE 25384-17-2 AMICARBALIDE 3459-96-9 ALLYLTHIOUREA 109-57-9 AMICIBONE 23271-63-8 ALMADRATE SULFATE 60239-66-9 AMICYCLINE 5874-95-3 ALMAGATE 66827-12-1 AMIDANTEL 49745-00-8 ALMAGODRATE AMIDAPSONE 3569-77-5 ALMASILATE 71205-22-6 AMIDEFRINE MESILATE 1421-68-7 ALMECILLIN 87-09-2 AMIFLAMINE 77518-07-1 ALMESTRONE 10448-96-1 AMIFLOVERINE 54063-24-0 ALMINOPROFEN 39718-89-3 AMIFLOXACIN 86393-37-5 ALMITRINE 27469-53-0 AMIFOSTINE 20537-88-6 ALMOKALANT 123955-10-2 AMIKACIN 37517-28-5 ALMOXATONE 84145-89-1 AMIKHELLINE 4439-67-2 ALNESPIRONE 138298-79-0 AMILORIDE 2609-46-3 ALNIDITAN 152317-89-0 AMINDOCATE 31386-24-0 ALONACIC 105292-70-4 AMINEPTINE 57574-09-1 ALONIMID 2897-83-8 AMINITROZOLE 140-40-9 ALORACETAM 119610-26-3 AMINOACRIDINE 90-45-9 ALOSETRON 122852-42-0 AMINOCAPROIC ACID 60-32-2 ALOVUDINE 25526-93-6 AMINOETHYL NITRATE 646-02-6 ALOXIPRIN 9014-67-9 AMINOGLUTETHIMIDE 125-84-8 ALOXISTATIN 88321-09-9 AMINOMETRADINE 642-44-4 ALOZAFONE 65899-72-1 AMINOPHENAZONE 58-15-1 ALPERTINE 27076-46-6 AMINOPHENAZONE CYCLAMATE 747-30-8 ALPHACETYLMETHADOL 17199-58-5 AMINOPHYLLINE 317-34-0 ALPHAMEPRODINE 468-51-9 AMINOPROMAZINE 58-37-7 ALPHAMETHADOL 17199-54-1 AMINOPTERIN SODIUM 58602-66-7 ALPHAPRODINE 77-20-3 AMINOQUINOL 10023-54-8 ALPIDEM 82626-01-5 AMINOQUINURIDE 3811-56-1 ALPIROPRIDE 81982-32-3 AMINOREX 2207-50-3 ALPRAFENONE 124316-02-5 AMINOTHIAZOLE 96-50-4 ALPRAZOLAM 28981-97-7 AMINOXYTRIPHENE 5585-64-8 ALPRENOLOL 13655-52-2 AMIODARONE 1951-25-3 ALPROSTADIL 745-65-3 AMIPERONE 1580-71-8 ALRESTATIN 51411-04-2 AMIPHENAZOLE 490-55-1 ALSACTIDE 34765-96-3 AMIPIZONE 69635-63-8 ALTANSERIN 76330-71-7 AMIPRILOSE 56824-20-5 ALTAPIZONE 93277-96-4 AMIQUINSIN 13425-92-8 ALTECONAZOLE 93479-96-0 AMISOMETRADINE 550-28-7 ALTEPLASE 105857-23-6 AMISULPRIDE 71675-85-9 ALTIZIDE 5588-16-9 AMITEROL 54063-25-1 ALTOQUALINE 121029-11-6 AMITIVIR 111393-84-1 ALTRENOGEST 850-52-2 AMITRAZ 33089-61-1 ALTRETAMINE 645-05-6 AMITRIPTYLINE 50-48-6 ALTUMOMAB 156586-92-4 AMITRIPTYLINOXIDE 4317-14-0 ALUMINIUM CLOFIBRATE 24818-79-9 AMIXETRINE 24622-72-8 ALUSULF 61115-28-4 AMLEXANOX 68302-57-8 ALVERINE 150-59-4 AMLODIPINE 88150-42-9 ALVIRCEPT SUDOTOX 137487-62-8 AMOBARBITAL 57-43-2 AMADINONE 30781-27-2 AMOCARZINE 36590-19-9 AMAFOLONE 50588-47-1 AMODIAQUINE 86-42-0 AMANOZINE 537-17-7 AMOGASTRIN 16870-37-4 AMANTADINE 768-94-5 AMOLANONE 76-65-3 AMANTANIUM BROMIDE 58158-77-3 AMONAFIDE 69408-81-7 AMANTOCILLIN 10004-67-8 AMOPROXAN 22661-76-3 AMBAMUSTINE 85754-59-2 AMOPYROQUINE 550-81-2 AMBASILIDE 83991-25-7 AMOROLFINE 78613-35-1 AMBAZONE 539-21-9 AMOSCANATE 26328-53-0 AMBENONIUM CHLORIDE 115-79-7 AMOSULALOL 85320-68-9 AMBENOXAN 2455-84-7 AMOXAPINE 14028-44-5 AMBICROMIL 58805-38-2 AMOXECAINE 553-65-1 AMBOMYCIN 1402-81-9 AMOXICILLIN 26787-78-0 AMBROXOL 18683-91-5 AMOXYDRAMINE CAMSILATE 15350-99-9 AMBRUTICIN 58857-02-6 AMPEROZIDE 75558-90-6 AMBUCAINE 119-29-9 AMPHENIDONE 134-37-2 AMBUCETAMIDE 519-88-0 AMPHOTALIDE 1673-06-9 AMBUSIDE 3754-19-6 AMPHOTERICIN B 1397-89-3 AMCINAFAL 3924-70-7 AMPICILLIN 69-53-4 AMCINAFIDE 7332-27-6 AMPIROXICAM 99464-64-9 AMCINONIDE 51022-69-6 AMPROLIUM 121-25-5 AMEBUCORT 83625-35-8 AMPYRIMINE 5587-93-9 AMEDALIN 22136-26-1 AMPYZINE 5214-29-9 AMELTOLIDE 787-93-9 AMQUINATE 17230-85-2 AMESERGIDE 121588-75-8 AMRINONE 60719-84-8 AMETANTRONE 64862-96-0 AMRUBICIN 110267-81-7 AMEZEPINE 60575-32-8 AMSACRINE 51264-14-3 AMEZINIUM METILSULFATE 30578-37-1 AMTOLMETIN GUACIL 87344-06-7 AMFEBUTAMONE 34911-55-2 AMYLMETACRESOL 1300-94-3 AMFECLORAL 5581-35-1 ANAGESTONE 2740-52-5 AMFENAC 51579-82-9 ANAGRELIDE 68475-42-3 AMFEPENTOREX 15686-27-8 ANAKINRA 143090-92-0 AMFEPRAMONE 90-84-6 ANARITIDE 95896-08-5 AMFETAMINE 300-62-9 ANASTROZOLE 120511-73-1 AMFETAMINIL 17590-01-1 ANAXIRONE 77658-97-0 AMFLUTIZOLE 82114-19-0 ANAZOCINE 15378-99-1 AMFOMYCIN 1402-82-0 ANAZOLENE SODIUM 3861-73-2 )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 5 Table 1 (con.) ProductCAS Number Product CAS Number ANCAROLOL 75748-50-4 ATAPROST 83997-19-7 ANCITABINE 31698-14-3 ATENOLOL 29122-68-7 ANCROD 9046-56-4 ATEVIRDINE 136816-75-6 ANDOLAST 132640-22-3 ATEXAKIN ALFA 143631-61-2 ANDROSTANOLONE 521-18-6 ATIBEPRONE 153420-96-3 ANGIOTENSIN II 4474-91-3 ATIPAMEZOLE 104054-27-5 ANGIOTENSINAMIDE 53-73-6 ATIPROSIN 89303-63-9 ANIDOXIME 34297-34-2 ATOLIDE 16231-75-7 ANILAMATE 5591-49-1 ATORVASTATIN 134523-00-5 ANILERIDINE 144-14-9 ATOSIBAN 90779-69-4 ANILOPAM 53716-46-4 ATOVAQUONE 95233-18-4 ANIPAMIL 83200-10-6 ATRACURIUM BESILATE 64228-81-5 ANIRACETAM 72432-10-1 ATRIMUSTINE 75219-46-4 ANIROLAC 66635-85-6 ATRINOSITOL 28841-62-5 ANISACRIL 5129-14-6 ATROMEPINE 428-07-9 ANISINDIONE 117-37-3 ATROPINE METHONITRATE 52-88-0 ANISOPIROL 442-03-5 ATROPINE OXIDE 4438-22-6 ANISTREPLASE 81669-57-0 AURANOFIN 34031-32-8 ANITRAZAFEN 63119-27-7 AUROTHIOGLYCANIDE 16925-51-2 ANPIRTOLINE 98330-05-3 AVICATONIN 103451-84-9 ANSOXETINE 79130-64-6 AVILAMYCIN 11051-71-1 ANTAFENITE 15301-45-8 AVIZAFONE 65617-86-9 ANTAZOLINE 91-75-8 AVOBENZONE 70356-09-1 ANTAZONITE 25422-75-7 AVOPARCIN 37332-99-3 ANTELMYCIN 1402-84-2 AVRIDINE 35607-20-6 ANTHIOLIMINE 305-97-5 AXAMOZIDE 85076-06-8 ANTIENITE 5029-05-0 AZABON 1150-20-5 ANTITHROMBIN III, HUMAN 9000-94-6 AZABUPERONE 2856-81-7 ANTRAFENINE 55300-29-3 AZACITIDINE 320-67-2 ANTRAMYCIN 4803-27-4 AZACLORZINE 49864-70-2 APAFANT 105219-56-5 AZACONAZOLE
Recommended publications
  • Meprobamate Art 107 AR

    Meprobamate Art 107 AR

    30 March 2012 EMA/212617/2012 Assessment report for meprobamate-containing medicinal products for oral use Procedure number: EMEA/H/A-107/1316 Procedure under Article 107 of Directive 2001/83/EC, as amended Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Discussion on safety ............................................................................................. 4 2.2.1. Non-clinical data ................................................................................................ 4 2.2.2. Clinical safety .................................................................................................... 4 2.2.2.1. Clinical studies ..............................................................................................
  • Automated Annotation of Structurally Uncharacterized Metabolites in Human Metabolomics Studies by Systems Biology Models

    Automated Annotation of Structurally Uncharacterized Metabolites in Human Metabolomics Studies by Systems Biology Models

    Technische Universität München Automated annotation of structurally uncharacterized metabolites in human metabolomics studies by systems biology models Jan-Dominik Bernd Quell 2019 Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt Technische Universität München Lehrstuhl für Experimentelle Bioinformatik Automated annotation of structurally uncharacterized metabo- lites in human metabolomics studies by systems biology models Jan-Dominik Bernd Quell Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Er- nährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigten Dissertation. Vorsitzender: Prof. Dr. Dmitrij Frischmann Prüfer der Dissertation: 1. Prof. Dr. Hans-Werner Mewes 2. Prof. Dr. Bernhard Küster Die Dissertation wurde am 28.11.2018 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 28.01.2019 angenommen. „Der Mensch muß bei dem Glauben verharren, daß das Unbegreifliche begreiflich sei; er würde sonst nicht forschen.“ Johann Wolfgang von Goethe i Danksagung Zunächst möchte ich mich ganz besonders bei meinem Doktorvater (Hans-)Werner Mewes bedanken, der mir nicht nur die Möglichkeit gegeben hat an seinem Institut des Helmholtz Zentrums München sowie seinem Lehrstuhl an der Technischen Uni- versität München in Forschung und Lehre zu arbeiten, sondern auch meine Laufbahn
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
  • Title Effects of N-Acetyl-Leucine and Its Enantiomers in Niemann-Pick

    Title Effects of N-Acetyl-Leucine and Its Enantiomers in Niemann-Pick

    bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title Effects of N-Acetyl-Leucine and its enantiomers in Niemann-Pick disease type C cells Danielle te Vruchte1, Anthony Galione2, Michael Strupp3 and Michiko Mann1 1IntraBio Ltd, Oxford University Begbroke Science Park, Woodstock Road, Oxford, UK 2Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK 3Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig Maximilians University, Munich, Germany Corresponding author Danielle te Vruchte Email: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Conflicts of Interest A.G. is a cofounder, shareholder and consultant to IntraBio. M.Y-M and D.t.V. are shareholders in IntraBio. M.S. acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion, is a shareholder of IntraBio and Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. M.S. has received speaker’s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grunenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
  • Identificación Computacional De Nuevos Compuestos Líderes Con Actividad Analgésica

    Identificación Computacional De Nuevos Compuestos Líderes Con Actividad Analgésica

    IDENTIFICACIÓN COMPUTACIONAL DE NUEVOS COMPUESTOS LÍDERES CON ACTIVIDAD ANALGÉSICA Autor: Earmin Shangoo. Tutores: Dr. Yovani Marrero Ponce MSc. Arelys López Sacerio Lic. Gerardo Maikel Casañola Martín “Año 49 de la Revolución Cubana” Curso 2006-2007 PENSAMIENTO “For all flesh is as grass, and all the glory of man as the flower of grass. The grass withereth, and the flower thereof falleth away: But the word of the Lord endureth for ever.” 1 Peter1:24,25. “Todo carne es como hierba y toda la gloria del hombre como flor de la hierba; la hierba se seca y la flor se cae, mas la palabra del Señor permanece para siempre.” 1 Pedro 1:24,25. DEDICATORIA For all my friends and family, especially my daughter, Naarah Melani Nerissa Athanase and my husband, Jeremiah Wayn Athanase, with love and admiration. “I have fought a good fight, I have finished my course…” 2Tim 4:7. Con mucho cariño y admiración, a todas mis amigos y mi familia en particular a mi hija, Naarah Melani Nerissa Athanase y mi esposo, Jeremiah Wayn Athanase. “He peleada la buena batalla, he acabado la carrera…” 2Ti 4:7 AGRADECIMIENTOS For me it is an enormous pleasure to be able to express my sincere gratefulness to all those people that in one way or another has helped me to successfully culminate my studies and this work. I would especially like to thank God because without him I am nothing; to my family for their faith, support, love and patience; to my tutors especially Arelys for their attention, dedication and orientation during this work; to all the professors of the career that made possible with their patient, constant and opportune help my formation as a pharmaceutical professional; to my friends, in particular to Solange and Harun; to all thank you.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS

    Pharmacology on Your Palms CLASSIFICATION of the DRUGS

    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive